Market Research Logo

Pemphigus Vulgaris - Pipeline Review, H2 2018

Pemphigus Vulgaris - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pemphigus Vulgaris - Pipeline Review, H2 2018, provides an overview of the Pemphigus Vulg


Introduction
Global Markets Direct Report Coverage
Pemphigus Vulgaris - Overview
Pemphigus Vulgaris - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Pemphigus Vulgaris - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Pemphigus Vulgaris - Companies Involved in Therapeutics Development
Argenx SE
Biogen Inc
HanAll Biopharma Co Ltd
Immunomedics Inc
Novartis AG
Principia Biopharma Inc
Rubius Therapeutics Inc
Syntimmune Inc
Pemphigus Vulgaris - Drug Profiles
Cellular Immunotherapy for Pemphigus Vulgaris - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DPC-006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
efgartigimod alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Pemphigus Vulgaris - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HL-161 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ianalumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
orilanolimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRN-1008 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rituximab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RTX-PV - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
veltuzumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Pemphigus Vulgaris - Dormant Projects
Pemphigus Vulgaris - Discontinued Products
Pemphigus Vulgaris - Product Development Milestones
Featured News & Press Releases
Jul 24, 2018: argenx announces publication of full data from Phase 1 healthy volunteer study of efgartigimod in Journal of Clinical Investigation
Jun 20, 2018: argenx reports interim data from first cohort of Phase 2 proof-of-concept clinical trial of efgartigimod for the treatment of pemphigus vulgaris
Jun 14, 2018: argenx announces data from Phase 1 study of efgartigimod (ARGX-113) subcutaneous formulation demonstrating comparable characteristics to intravenous formulation
Jun 07, 2018: FDA Approves Genentech's Rituxan (rituximab) For Pemphigus Vulgaris
Feb 13, 2018: FDA Grants Priority Review for Genentech’s Rituxan (Rituximab) for Pemphigus Vulgaris
Dec 11, 2017: argenx reports positive topline results from Phase 2 proof-of-concept trial of ARGX-113 (efgartigimod) in generalized myasthenia gravis
Nov 02, 2017: Argenx to Host KOL Breakfast Symposium on Pemphigus Vulgaris
Oct 30, 2017: Argenx Launches Phase I Trial with Subcutaneous Formulation of ARGX-113
Sep 26, 2017: argenx launches Phase II proof-of-concept clinical trial of ARGX-113 for the treatment of pemphigus vulgaris
Sep 18, 2017: Principia Biopharma Presents Late-Breaking Interim Phase 2 Data of PRN1008 in Pemphigus at European Academy of Dermatology and Venereology Meeting
Jul 11, 2017: Principia Biopharma Announces PRN1008 Receives Orphan Drug Designation From FDA for Treatment of Pemphigus Vulgaris
Mar 24, 2017: FDA grants breakthrough therapy designation for MabThera/Rituxan (rituximab) in pemphigus vulgaris
Jan 07, 2016: Principia Biopharma Advances BTK Inhibitor Program in Autoimmune Disease and FGFR Inhibitor Program in Oncology
Aug 25, 2015: Genentech Initiates Phase III Trial of Rituxan for Rare, Autoimmune Disease: Pemphigus Vulgaris
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Pemphigus Vulgaris, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pemphigus Vulgaris - Pipeline by Argenx SE, H2 2018
Pemphigus Vulgaris - Pipeline by Biogen Inc, H2 2018
Pemphigus Vulgaris - Pipeline by HanAll Biopharma Co Ltd, H2 2018
Pemphigus Vulgaris - Pipeline by Immunomedics Inc, H2 2018
Pemphigus Vulgaris - Pipeline by Novartis AG, H2 2018
Pemphigus Vulgaris - Pipeline by Principia Biopharma Inc, H2 2018
Pemphigus Vulgaris - Pipeline by Rubius Therapeutics Inc, H2 2018
Pemphigus Vulgaris - Pipeline by Syntimmune Inc, H2 2018
Pemphigus Vulgaris - Dormant Projects, H2 2018
Pemphigus Vulgaris - Discontinued Products, H2 2018
List of Figures
Number of Products under Development for Pemphigus Vulgaris, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products by Targets, H2 2018
Number of Products by Stage and Targets, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Top 10 Molecule Types, H2 2018
Number of Products by Stage and Top 10 Molecule Types, H2 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report